Rezdiffra (Resmetirom) and Gabapentin Interaction: Safety, Risks, and Clinical Guidance
Resmetirom (brand name Rezdiffra) is an oral thyroid hormone receptor-beta (THR-beta) agonist that the FDA approved in March 2024 for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH, formerly called NASH) with moderate-to-advanced liver fibrosis (stages F2-F3), used alongside diet and exercise. Gabapentin (brand name Neurontin, generic widely available) is an anticonvulsant and neuropathic pain agent, structurally related to GABA but not acting on GABA receptors, approved for postherpetic neuralgia and as adjunctive epilepsy therapy, and used off-label for many other pain and sleep-related conditions.
This article addresses whether the two can be combined and what a clinician or pharmacist should actually check before assuming the combination is routine.
No dedicated drug-drug interaction study of resmetirom and gabapentin exists, and neither the Rezdiffra label nor the Neurontin/gabapentin label lists the other drug as a contraindication or precaution. Resmetirom is metabolized hepatically, primarily by CYP3A4 with a secondary contribution from CYP2C8, and its uptake depends on liver transporters (OATP1B1/1B3); gabapentin undergoes no hepatic metabolism at all and is eliminated unchanged by the kidneys. Because their disposition pathways do not overlap, a direct pharmacokinetic interaction is not mechanistically expected. The more realistic concern is pharmacodynamic and indirect: additive central nervous system depression, and the possibility that resmetirom-induced thyroid hormone shifts could alter how a patient's neuropathic pain and gabapentin response are perceived over time.
Why this combination comes up in practice
People with MASH often carry the metabolic comorbidities (diabetes, obesity, peripheral neuropathy) for which gabapentin is commonly prescribed, so hepatologists and primary care clinicians are likely to encounter this pairing. Because resmetirom is a comparatively new drug, the evidence base for its interactions with commonly co-prescribed agents comes primarily from its FDA-mandated pharmacokinetic program and label, not from real-world combination studies with gabapentin specifically. That gap should be stated plainly rather than papered over with confident-sounding numbers.
Where the two drugs' pharmacokinetics diverge
Resmetirom's FDA label identifies CYP3A4 as the primary metabolizing enzyme, with CYP2C8 contributing secondarily, and flags OATP1B1/1B3 transporters as important to its hepatic uptake. The label warns against combining resmetirom with strong CYP3A4 inducers and notes that strong CYP3A4 or OATP1B1/1B3 inhibitors can raise resmetirom exposure (FDA label, accessed 2024 approval).
Gabapentin, by contrast, is not a substrate, inhibitor, or inducer of any CYP enzyme. It is absorbed via a saturable intestinal transporter (the L-amino acid transport system), circulates with minimal protein binding, and is cleared by the kidneys essentially unchanged; dosing is reduced for people with impaired renal function (FDA Neurontin label). Because gabapentin never enters the CYP system and resmetirom's clearance does not depend on the kidneys, the two drugs occupy separate elimination pathways. This is the pharmacologic basis for saying a direct interaction is unlikely, not proof that the combination has been formally tested and found safe.
Could resmetirom affect gabapentin indirectly through the kidneys?
This is worth asking because gabapentin blood levels track renal function closely. Thyroid hormone excess, whether from endogenous hyperthyroidism or exogenous therapy, is known to increase renal blood flow and glomerular filtration in some patients. Resmetirom is a selective THR-beta agonist designed to concentrate its effect in the liver, and its label does not describe a renal-function signal as part of its safety profile. Whether resmetirom's more limited systemic thyroid activity produces any measurable change in glomerular filtration rate has not been established through the sources reviewed here, and a precise answer would require checking the pivotal trial's renal safety data directly against the current label rather than relying on a secondhand summary. For a patient who already has chronic kidney disease and an already-reduced gabapentin dose, this is a reasonable point to flag with a clinician even though it remains theoretical rather than documented.
The real pharmacodynamic overlap: sedation
Gabapentin carries an FDA warning about respiratory depression when combined with other central nervous system depressants, a concern regulators have also highlighted separately regarding gabapentin and related gabapentinoids causing serious breathing problems, particularly in combination with opioids, in older adults, and in people with respiratory disease. Gabapentin alone commonly causes somnolence and dizziness in a meaningful minority of patients according to its label's adverse-reaction data.
Resmetirom's label does not describe sedation as a prominent adverse effect; its most commonly reported adverse effects in the pivotal program were gastrointestinal (diarrhea and nausea), not CNS-related. THR-beta receptors are expressed in the brain, and some systemic (non-hepatic) exposure to resmetirom does occur despite its liver-selective design, so a contribution to fatigue or mild cognitive change cannot be ruled out on pharmacologic grounds. But this is plausible reasoning, not a documented adverse-event signal from a comparative trial. The combination's realistic risk is additive drowsiness and dizziness from gabapentin, in a patient who happens also to be taking resmetirom, rather than resmetirom independently amplifying gabapentin's sedative effect through any known mechanism.
Transporter-level reassurance
Resmetirom's label identifies it as a substrate of OATP1B1/1B3 and as an inhibitor of BCRP at clinically relevant concentrations, which is why the label flags interactions with OATP inhibitors (such as cyclosporine) and BCRP substrates (such as rosuvastatin). Gabapentin is not a substrate of OATP1B1, OATP1B3, BCRP, or P-glycoprotein; its absorption depends on a separate amino-acid transporter in the gut. Because gabapentin does not touch any of the transporter systems resmetirom is known to affect, this is one area where the pharmacology offers genuine reassurance rather than simply an absence of data.
Thyroid hormone shifts and what they might mean for gabapentin's job
Resmetirom's mechanism (THR-beta agonism) is expected to suppress TSH and can lower circulating thyroid hormone levels through feedback on the hypothalamic-pituitary-thyroid axis; periodic thyroid monitoring is part of its labeled recommendations. This matters for a patient on gabapentin because both hypothyroidism and subclinical thyroid dysfunction have long been associated with worsened peripheral neuropathy and altered pain perception in the general literature on diabetic and metabolic neuropathy. If resmetirom shifts a patient's thyroid status while they are being treated with gabapentin for neuropathic pain, a patient reporting "gabapentin isn't working anymore" could actually be experiencing a thyroid-axis effect rather than tachyphylaxis or disease progression. The exact monitoring interval recommended in the current label should be confirmed directly against the prescribing information at the time of use, since label language can be revised.
Who needs closer attention
Not every patient taking both drugs needs the same level of surveillance.
Patients who warrant closer monitoring include those over 65, anyone with reduced kidney function (gabapentin dosing is already renally adjusted in this group), patients taking additional CNS-active medications (opioids, benzodiazepines, sedating antihistamines, sleep aids), and anyone with a history of falls or respiratory disease. For these patients, a baseline check of renal function, a thyroid panel, and a specific conversation about daytime sedation before and shortly after starting resmetirom is reasonable clinical practice, even though no guideline mandates this specific combination-monitoring protocol.
Patients without these risk factors can generally follow the routine monitoring already recommended in the resmetirom label (liver enzymes and thyroid function at baseline and periodically) without additional gabapentin-specific testing, unless new symptoms appear.
Should the gabapentin dose change when starting resmetirom?
Neither label requires a dose adjustment when the two drugs are used together, and no dedicated interaction study has established one. If a patient develops new or worsened drowsiness after adding resmetirom to a stable gabapentin regimen, the reasonable clinical response is to reassess the gabapentin dose based on symptoms and pain control, rather than to apply a fixed percentage reduction, since no trial data support a specific dose-adjustment formula for this pair. Starting the two drugs a few weeks apart, rather than simultaneously, can help a clinician attribute any new adverse effect to a single agent. This is general prescribing judgment, not a labeled instruction.
What "no interaction" actually means here
Drug interaction databases generally do not flag resmetirom plus gabapentin as clinically significant, and that reflects the non-overlapping metabolic pathways described above. It is worth being explicit about what that absence means: it means the known pharmacology does not predict an interaction, not that the combination has been prospectively studied and confirmed safe. The resmetirom label's specific interaction warnings (CYP3A4 modulators, OATP inhibitors, BCRP substrates such as rosuvastatin) exist because those pathways were tested in dedicated pharmacokinetic studies during drug development. Gabapentin was not part of that program because its pharmacology gave no mechanistic reason to test it, which is a reasonable basis for confidence but not the same as direct evidence.
Evidence-status interaction assessment
| Claim | Status | Basis | What to verify before relying on it |
|---|---|---|---|
| No CYP- or transporter-mediated PK interaction between resmetirom and gabapentin | Established (mechanistic) | Resmetirom label describes CYP3A4/CYP2C8 and OATP/BCRP handling; gabapentin label describes renal elimination with no CYP or transporter involvement | Confirm current label language has not changed since last review |
| No dedicated clinical DDI study has tested this specific pair | Established | Absence from resmetirom's DDI program and from major interaction databases | Check interaction database version date at time of prescribing |
| Additive CNS sedation (drowsiness, dizziness) is possible | Plausible, pharmacodynamic | Gabapentin's known sedation profile plus general CNS-depressant caution; resmetirom does not independently carry a sedation warning | Screen for sedation clinically; no validated combined-risk score exists |
| Resmetirom-induced thyroid suppression could alter gabapentin's apparent efficacy for neuropathic pain | Plausible, indirect | THR-beta mechanism and general association between thyroid dysfunction and neuropathic symptoms | Confirm thyroid panel timing against current label; distinguish thyroid effect from disease progression clinically |
| Resmetirom changes gabapentin renal clearance through altered GFR | Not established | No renal-function signal described in the resmetirom label; theoretical only | Would require dedicated renal pharmacokinetic data, which does not currently exist for this pair |
| A specific gabapentin dose-reduction percentage is appropriate when starting resmetirom | Not established | No trial or label basis for a fixed adjustment | Base any dose change on individual symptoms and pain control, not a formula |
Evidence boundary
What is established: the two drugs are cleared through separate, non-overlapping pathways (hepatic CYP/transporter metabolism for resmetirom, unchanged renal excretion for gabapentin), and neither label lists the other as a contraindicated or precautionary combination. What is plausible but unproven: additive sedation from combining any CNS-active gabapentin regimen with a new medication, and a possible indirect effect of resmetirom's thyroid-suppressing mechanism on how well gabapentin controls neuropathic symptoms. What is not established: any renal, dosing, or monitoring protocol specific to this exact combination, since no dedicated interaction trial or long-term real-world dataset for resmetirom plus gabapentin was identified in the sources reviewed for this article.
When to seek urgent care
New confusion, difficulty waking, slowed or shallow breathing, or a fall should prompt urgent medical evaluation regardless of which medications are involved, particularly in an older adult or anyone also taking an opioid or benzodiazepine. Ongoing new drowsiness that is not urgent but is affecting daily function or driving safety should be discussed with the prescriber promptly rather than waiting for a routine follow-up.
Patient counseling points
People taking both medications should be told to report new or worsening drowsiness, dizziness, or trouble concentrating, especially in the first several weeks after starting resmetirom, and to avoid driving until they know how the combination affects them. Alcohol adds both sedative risk on top of gabapentin and additional hepatic stress in a patient already being treated for liver disease, so it deserves an explicit conversation. Because these patients often see more than one prescriber (a hepatologist for MASH and a separate clinician for pain or neurologic care), keeping a single accurate medication list matters more than it might for a patient on one drug from one prescriber.
Frequently asked questions
Can I take Rezdiffra (resmetirom) with gabapentin?
Is it safe to combine Rezdiffra and gabapentin?
Does resmetirom affect how gabapentin is absorbed or eliminated?
Should I adjust my gabapentin dose when starting Rezdiffra?
Can resmetirom change my thyroid levels enough to affect other medications?
What are the most significant known drug interactions with Rezdiffra?
Can I drink alcohol while taking both resmetirom and gabapentin?
Do I need extra blood tests if I take both drugs together?
References
- U.S. Food and Drug Administration. Rezdiffra (resmetirom) prescribing information, approved March 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217785s000lbl.pdf
- U.S. Food and Drug Administration. Neurontin (gabapentin) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf
Several claims about trial-specific efficacy percentages, exact monitoring intervals, and secondary literature on thyroid function and neuropathy that appeared in an earlier draft of this article could not be verified against a confirmed primary source and have been removed or narrowed. Anyone relying on this article clinically should confirm current label language directly with the FDA prescribing information before making a treatment decision.